UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Journal of translational medicine, 2007-07, Vol.5 (1), p.32-32, Article 32

2007

Volltextzugriff (PDF)

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-01, Vol.24 (1), p.16-24

2006

Volltextzugriff (PDF)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534

Scientific reports, 2021-05, Vol.11 (1), p.11066-14, Article 11066

2021

Volltextzugriff (PDF)

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3743-3748

2008

Volltextzugriff (PDF)

Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study

British journal of dermatology (1951), 2023-04, Vol.188 (5), p.601-609

2023

Volltextzugriff (PDF)

Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial

Journal of investigative dermatology, 2018-09, Vol.138 (9), p.1973-1981

2018

Volltextzugriff (PDF)

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Journal of clinical oncology, 2006-01, Vol.24 (1), p.25-35

2006

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

Clinical cancer research, 2010-03, Vol.16 (6), p.1924-1937

2010

Volltextzugriff (PDF)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534

Scientific reports, 2022-04, Vol.12 (1), p.5740-5740, Article 5740

2022

Volltextzugriff (PDF)

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

The lancet oncology, 2009-08, Vol.10 (8), p.794-800

2009

Volltextzugriff (PDF)

Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4793-4799

2007

Volltextzugriff (PDF)

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity

Blood, 2006-09, Vol.108 (5), p.1744-1750

2006

Volltextzugriff (PDF)

Toreforant, an orally active histamine H 4 -receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation research, 2019-04, Vol.68 (4), p.261

2019

Volltextzugriff (PDF)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

Cancer chemotherapy and pharmacology, 2014, Vol.73 (1), p.151-161

2014

Volltextzugriff (PDF)

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

JID innovations, 2024-09, Vol.4 (5), p.100287, Article 100287

2024

Volltextzugriff (PDF)

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation research, 2019-04, Vol.68 (4), p.261-274

2019

Volltextzugriff (PDF)

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy

JID innovations, 2024-09, Vol.4 (5), p.100297, Article 100297

2024

Volltextzugriff (PDF)

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

Clinical cancer research, 2009-09, Vol.15 (18), p.5869-5877

2009

Volltextzugriff (PDF)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

Journal of translational medicine, 2012-08, Vol.10 (1), p.165-165, Article 165

2012

Volltextzugriff (PDF)

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

Journal of translational medicine, 2011-07, Vol.9 (1), p.120-120, Article 120

2011

Volltextzugriff (PDF)

Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells

Cancer epidemiology, biomarkers & prevention, 2005-03, Vol.14 (3), p.596-604

2005

Volltextzugriff (PDF)

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

BMC cancer, 2003-02, Vol.3 (1), p.3-3, Article 3

2003

Volltextzugriff (PDF)

Transcriptional programs activated by exposure of human prostate cancer cells to androgen

Genome biology, 2002-06, Vol.3 (7), p.RESEARCH0032-research0032.12, Article research0032.1

2002

Volltextzugriff (PDF)

Mechanisms of G2 arrest in response to overexpression of p53

Molecular biology of the cell, 1999-11, Vol.10 (11), p.3607-3622

1999

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(39)
Dissertationen
(1)

Sprache

Englisch
(40)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(28)
Humans
(27)
Male
(18)
Biological And Medical Sciences
(15)
Female
(15)
Middle Aged
(14)
Aged
(13)
Medical Sciences
(13)
Oncology
(13)
Adult
(12)
Indoles - Therapeutic Use
(10)
Pyrroles - Therapeutic Use
(10)
Biomarkers, Tumor - Blood
(8)
Tumors
(8)
Aged, 80 And Over
(6)
Antineoplastic Agents - Therapeutic Use
(6)
Biomarkers
(6)
Animals
(5)
Mice
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study

Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity

Toreforant, an orally active histamine H 4 -receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

Transcriptional programs activated by exposure of human prostate cancer cells to androgen

Mechanisms of G2 arrest in response to overexpression of p53

Suchergebnisse filtern